Cargando…

Commentary: Parkinson's Disease Genes VPS35 and EIF4G1 Interact Genetically and Converge on α-Synuclein

Detalles Bibliográficos
Autores principales:	Olszewska, Diana A., McCarthy, Allan, Lynch, Tim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2016
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834707/ https://www.ncbi.nlm.nih.gov/pubmed/27147954 http://dx.doi.org/10.3389/fnins.2016.00162

Ejemplares similares

VPS35 and α-Synuclein fail to interact to modulate neurodegeneration in rodent models of Parkinson’s disease
por: Chen, Xi, et al.
Publicado: (2023)

Screening for VPS35 mutations in Parkinson's disease
por: Sheerin, Una-Marie, et al.
Publicado: (2012)

VPS35, the Retromer Complex and Parkinson’s Disease
por: Williams, Erin T., et al.
Publicado: (2017)

High expression levels of the D686N Parkinson's disease mutation in VPS35 induces α-synuclein-dependent toxicity in yeast
por: Huang, Yi, et al.
Publicado: (2017)

The Convergence of Dopamine and α-Synuclein: Implications for Parkinson’s Disease
por: Mor, Danielle E, et al.
Publicado: (2018)

VPS54 and the wobbler mouse
por: Schmitt-John, Thomas
Publicado: (2015)

VPS35 Parkinson mutation impairs autophagy via WASH
por: Zavodszky, Eszter, et al.
Publicado: (2014)

VPS35, the core component of the retromer complex, and Parkinson's disease
por: Luo, Ai‐Di, et al.
Publicado: (2021)

Commentary: Evaluation of Models of Parkinson's Disease
por: Muñoz, Patricia, et al.
Publicado: (2016)

Commentary: Evaluation of Models of Parkinson's Disease
por: Leal, Pollyana C., et al.
Publicado: (2016)

Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration
por: Tsika, Elpida, et al.
Publicado: (2014)

Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson's disease
por: Gallegos, Scarlet, et al.
Publicado: (2015)

Corrigendum: Commentary: Evaluation of Models of Parkinson's Disease
por: Muñoz, Patricia, et al.
Publicado: (2016)

VPS35-Based Approach: A Potential Innovative Treatment in Parkinson's Disease
por: Eleuteri, Simona, et al.
Publicado: (2019)

Alpha-synuclein Toxicity in the Early Secretory Pathway: How It Drives Neurodegeneration in Parkinsons Disease
por: Wang, Ting, et al.
Publicado: (2015)

Convergence of miRNA Expression Profiling, α-Synuclein Interacton and GWAS in Parkinson's Disease
por: Martins, Madalena, et al.
Publicado: (2011)

VPS35 leaves endosomes lost in transition
por: Leslie, Mitch
Publicado: (2011)

Mutation in VPS35 associated with Parkinson’s disease impairs WASH complex association and inhibits autophagy
por: Zavodszky, Eszter, et al.
Publicado: (2014)

VPS35 D620N knockin mice recapitulate cardinal features of Parkinson’s disease
por: Niu, Mengyue, et al.
Publicado: (2021)

Commentary: Discriminating α-synuclein strains in parkinson's disease and multiple system atrophy
por: Fellner, Lisa, et al.
Publicado: (2020)

Will Crystal Parkin Help in Understanding the Future of Parkinson’s Disease?
por: Olszewska, Diana Angelika, et al.
Publicado: (2015)

Endosome to Golgi Retrieval of the Vacuolar Protein Sorting Receptor, Vps10p, Requires the Function of the VPS29, VPS30, and VPS35 Gene Products
por: Seaman, Matthew N.J., et al.
Publicado: (1997)

Association Between Glucocerebrosidase Mutations and Parkinson's Disease in Ireland
por: Olszewska, Diana A., et al.
Publicado: (2020)

The AAA-ATPase VPS4 Regulates Extracellular Secretion and Lysosomal Targeting of α-Synuclein
por: Hasegawa, Takafumi, et al.
Publicado: (2011)

Parkinson’s disease-associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes
por: Wang, Wenzhang, et al.
Publicado: (2015)

Familial atypical parkinsonism with rare variant in VPS35 and FBXO7 genes: A case report
por: Bartonikova, Tereza, et al.
Publicado: (2016)

Elevated urine BMP phospholipids in LRRK2 and VPS35 mutation carriers with and without Parkinson’s disease
por: Gomes, Sara, et al.
Publicado: (2023)

VPS35 haploinsufficiency increases Alzheimer’s disease neuropathology
por: Wen, Lei, et al.
Publicado: (2011)

In vivo evidence of pathogenicity of VPS35 mutations in the Drosophila
por: Wang, Hua-shan, et al.
Publicado: (2014)

VPS35 regulates tau phosphorylation and neuropathology in tauopathy
por: Vagnozzi, Alana N., et al.
Publicado: (2021)

Convergent Validity of the PUTS
por: Brandt, Valerie Cathérine, et al.
Publicado: (2016)

A Wolf in Sheep’s Clothing: An “Alien Leg” in Corticobasal Syndrome
por: Olszewska, Diana Angelika, et al.
Publicado: (2017)

Novel gene (TMEM230) linked to Parkinson’s disease
por: Olszewska, Diana A., et al.
Publicado: (2016)

Ocular Convergence Deficits in Schizophrenia
por: Bolding, Mark S., et al.
Publicado: (2012)

Parkinson’s Disease Causative Mutation in Vps35 Disturbs Tetherin Trafficking to Cell Surfaces and Facilitates Virus Spread
por: Ding, Yingzhuo, et al.
Publicado: (2021)

VPS35 depletion does not impair presynaptic structure and function
por: Vazquez-Sanchez, Sonia, et al.
Publicado: (2018)

New Perception of Mitochondrial Regulatory Pathway in Parkinsonism – Ubiquitin, PINK1, and Parkin
por: Olszewska, Diana Angelika, et al.
Publicado: (2014)

Endonuclease G mediates α-synuclein cytotoxicity during Parkinson’s disease
por: Büttner, Sabrina, et al.
Publicado: (2013)

The yeast prion protein Sup35 initiates α-synuclein pathology in mouse models of Parkinson’s disease
por: Meng, Lanxia, et al.
Publicado: (2023)

Commentary: α-Synuclein Interacts with Lipoproteins in Plasma
por: Surguchov, Andrei
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_he1l7ej15p1nfme6e5e3vht436